Rallybio CorporationRLYBNASDAQ
Loading
RLYB Revenue Growth (YoY Quarterly)•+484.21%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+484.21%
+513.3pp
+2637.50%
+2666.6pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
-5.36%
-6.4pp
-5.36%
-6.4pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -83.33% | +0.00% | -29.10% | -29.10% | +484.21% |
| Gross Profit Growth | -92.98% | +0.00% | -20.00% | -29.10% | +2637.50% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +9.89% | +9.81% | +1.62% | +1.04% | -5.36% |
| Weighted Average Shares Diluted Growth | +9.89% | +9.81% | +1.62% | +1.04% | -5.36% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -41.09% | -41.64% | -44.82% | -14.36% | -8.58% |
| Book Value per Share Growth | -47.16% | -44.77% | -43.47% | -11.91% | -0.67% |
| Debt Growth | -60.71% | -65.78% | -79.58% | -13.91% | +14.29% |
| R&D Expense Growth | -53.81% | -55.62% | -52.96% | -49.72% | -50.35% |
| SG&A Expenses Growth | -17.87% | -39.32% | -4.40% | -27.42% | -30.09% |
1 / 4